P. Royston

发表

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

M. Parmar, M. Sydes, D. Dearnaley, 2009, Trials.

Speeding up the Evaluation of New Agents in Cancer

M. Parmar, M. Sydes, E. Eisenhauer, 2008, Journal of the National Cancer Institute.

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome

M. Parmar, J. Bowden, P. Royston, 2013, Trials.

Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols

M. Parmar, M. Sydes, P. Royston, 2017, Clinical trials.

State of the art in selection of variables and functional forms in multivariable analysis—outstanding issues

Willi Sauerbrei, Geraldine Rauch, Harald Binder, 2019, Diagnostic and Prognostic Research.

How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design – a reanalysis of 4 trials

P. Royston, F. M. Barthel, FM-S Barthel, 2009, Trials.

Evaluation of sample size and power for multi‐arm survival trials allowing for non‐uniform accrual, non‐proportional hazards, loss to follow‐up and cross‐over

P Royston, P. Royston, P. Royston, 2006, Statistics in medicine.

artcat: Sample-size calculation for an ordered categorical outcome

Ian R. White, P. Royston, T. Morris, 2023, The Stata journal.

artbin: Extended sample size for randomized trials with binary outcomes

Ian R. White, P. Royston, A. Babiker, 2023, The Stata journal.